199 related articles for article (PubMed ID: 22248277)
1. Evaluation of alpha-methylacyl-CoA racemase, metallothionein and prostate specific antigen as prostate cancer prognostic markers.
Gumulec J; Masarik M; Krizkova S; Hlavna M; Babula P; Hrabec R; Rovny A; Masarikova M; Sochor J; Adam V; Eckschlager T; Kizek R
Neoplasma; 2012; 59(2):191-201. PubMed ID: 22248277
[TBL] [Abstract][Full Text] [Related]
2. Global expression of AMACR transcripts predicts risk for prostate cancer - a systematic comparison of AMACR protein and mRNA expression in cancerous and noncancerous prostate.
Alinezhad S; Väänänen RM; Ochoa NT; Vertosick EA; Bjartell A; Boström PJ; Taimen P; Pettersson K
BMC Urol; 2016 Feb; 16():10. PubMed ID: 26928323
[TBL] [Abstract][Full Text] [Related]
3. High alpha-methylacyl-CoA racemase (AMACR) is associated with ERG expression and with adverse clinical outcome in patients with localized prostate cancer.
Box A; Alshalalfa M; Hegazy SA; Donnelly B; Bismar TA
Tumour Biol; 2016 Sep; 37(9):12287-12299. PubMed ID: 27271990
[TBL] [Abstract][Full Text] [Related]
4. Kinetic fluorescence reverse transcriptase-polymerase chain reaction for alpha-methylacyl CoA racemase distinguishes prostate cancer from benign lesions.
Schostak M; Miller K; Krause H; Schrader M; Kempkensteffen C; Kollermann J
Cancer Detect Prev; 2006; 30(5):449-54. PubMed ID: 17067752
[TBL] [Abstract][Full Text] [Related]
5. Prostate Cancer Diagnosis Using Urine Sediment Analysis-Based α-Methylacyl-CoA Racemase Score: A Single-Center Experience.
Ji J; Chen X; Xu Y; Cao Z; Xu H; Kong C; Wang F; Sun Y
Cancer Control; 2019; 26(1):1073274819887697. PubMed ID: 31793344
[TBL] [Abstract][Full Text] [Related]
6. Alpha-methylacyl-CoA racemase: a multi-institutional study of a new prostate cancer marker.
Jiang Z; Wu CL; Woda BA; Iczkowski KA; Chu PG; Tretiakova MS; Young RH; Weiss LM; Blute RD; Brendler CB; Krausz T; Xu JC; Rock KL; Amin MB; Yang XJ
Histopathology; 2004 Sep; 45(3):218-25. PubMed ID: 15330799
[TBL] [Abstract][Full Text] [Related]
7. Humoral immune response to alpha-methylacyl-CoA racemase and prostate cancer.
Sreekumar A; Laxman B; Rhodes DR; Bhagavathula S; Harwood J; Giacherio D; Ghosh D; Sanda MG; Rubin MA; Chinnaiyan AM
J Natl Cancer Inst; 2004 Jun; 96(11):834-43. PubMed ID: 15173267
[TBL] [Abstract][Full Text] [Related]
8. Decreased alpha-methylacyl CoA racemase expression in localized prostate cancer is associated with an increased rate of biochemical recurrence and cancer-specific death.
Rubin MA; Bismar TA; Andrén O; Mucci L; Kim R; Shen R; Ghosh D; Wei JT; Chinnaiyan AM; Adami HO; Kantoff PW; Johansson JE
Cancer Epidemiol Biomarkers Prev; 2005 Jun; 14(6):1424-32. PubMed ID: 15941951
[TBL] [Abstract][Full Text] [Related]
9. Foamy gland carcinoma of the prostate in needle biopsy: incidence, Gleason grade, and comparative α-methylacyl-CoA racemase vs. ERG expression.
Warrick JI; Humphrey PA
Am J Surg Pathol; 2013 Nov; 37(11):1709-14. PubMed ID: 23797726
[TBL] [Abstract][Full Text] [Related]
10. alpha-Methylacyl coenzyme A racemase as a tissue biomarker for prostate cancer.
Rubin MA; Zhou M; Dhanasekaran SM; Varambally S; Barrette TR; Sanda MG; Pienta KJ; Ghosh D; Chinnaiyan AM
JAMA; 2002 Apr; 287(13):1662-70. PubMed ID: 11926890
[TBL] [Abstract][Full Text] [Related]
11. Alpha-methylacyl-CoA racemase: a new molecular marker for prostate cancer.
Luo J; Zha S; Gage WR; Dunn TA; Hicks JL; Bennett CJ; Ewing CM; Platz EA; Ferdinandusse S; Wanders RJ; Trent JM; Isaacs WB; De Marzo AM
Cancer Res; 2002 Apr; 62(8):2220-6. PubMed ID: 11956072
[TBL] [Abstract][Full Text] [Related]
12. α-Methylacyl-CoA racemase expression and lethal prostate cancer in the Physicians' Health Study and Health Professionals Follow-up Study.
Barry M; Dhillon PK; Stampfer MJ; Perner S; Ma J; Giovannucci E; Kurth T; Mucci LA; Rubin MA
Prostate; 2012 Feb; 72(3):301-6. PubMed ID: 21713964
[TBL] [Abstract][Full Text] [Related]
13. Detection of alpha-methylacyl-coenzyme-A racemase transcripts in blood and urine samples of prostate cancer patients.
Zehentner BK; Secrist H; Zhang X; Hayes DC; Ostenson R; Goodman G; Xu J; Kiviat M; Kiviat N; Persing DH; Houghton RL
Mol Diagn Ther; 2006; 10(6):397-403. PubMed ID: 17154657
[TBL] [Abstract][Full Text] [Related]
14. Induction of alpha-methylacyl-CoA racemase by miR-138 via up-regulation of β-catenin in prostate cancer cells.
Erdmann K; Kaulke K; Rieger C; Wirth MP; Fuessel S
J Cancer Res Clin Oncol; 2017 Nov; 143(11):2201-2210. PubMed ID: 28741117
[TBL] [Abstract][Full Text] [Related]
15. Alpha-methylacyl-CoA racemase and hepsin as urinary prostate cancer markers.
Sroka WD; Adamowski M; Słupski P; Siódmiak J; Jarzemski P; Odrowąż-Sypniewska G; Marszałł MP
Int J Biol Markers; 2015 Nov; 30(4):e401-6. PubMed ID: 25982684
[TBL] [Abstract][Full Text] [Related]
16. The prostate-specific G-protein coupled receptors PSGR and PSGR2 are prostate cancer biomarkers that are complementary to alpha-methylacyl-CoA racemase.
Wang J; Weng J; Cai Y; Penland R; Liu M; Ittmann M
Prostate; 2006 Jun; 66(8):847-57. PubMed ID: 16491480
[TBL] [Abstract][Full Text] [Related]
17. GOLPH2 protein expression as a novel tissue biomarker for prostate cancer: implications for tissue-based diagnostics.
Kristiansen G; Fritzsche FR; Wassermann K; Jäger C; Tölls A; Lein M; Stephan C; Jung K; Pilarsky C; Dietel M; Moch H
Br J Cancer; 2008 Sep; 99(6):939-48. PubMed ID: 18781151
[TBL] [Abstract][Full Text] [Related]
18. Comparison of annexin II, p63 and alpha-methylacyl-CoA racemase immunoreactivity in prostatic tissue: a tissue microarray study.
Stewart J; Fleshner N; Cole H; Sweet J
J Clin Pathol; 2007 Jul; 60(7):773-80. PubMed ID: 16916997
[TBL] [Abstract][Full Text] [Related]
19. Elevated alpha-methylacyl-CoA racemase enzymatic activity in prostate cancer.
Kumar-Sinha C; Shah RB; Laxman B; Tomlins SA; Harwood J; Schmitz W; Conzelmann E; Sanda MG; Wei JT; Rubin MA; Chinnaiyan AM
Am J Pathol; 2004 Mar; 164(3):787-93. PubMed ID: 14982833
[TBL] [Abstract][Full Text] [Related]
20. Alpha-methylacyl-CoA racemase (P504S)/34betaE12/p63 triple cocktail stain in prostatic adenocarcinoma after hormonal therapy.
Sung MT; Jiang Z; Montironi R; MacLennan GT; Mazzucchelli R; Cheng L
Hum Pathol; 2007 Feb; 38(2):332-41. PubMed ID: 17134736
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
